Proteomics International Laboratories Ltd

AU:PIQ Australia Biotechnology
Market Cap
$32.73 Million
AU$52.86 Million AUD
Market Cap Rank
#24518 Global
#504 in Australia
Share Price
AU$0.32
Change (1 day)
-3.03%
52-Week Range
AU$0.29 - AU$0.84
All Time High
AU$1.35
Categories
Companies in Australia Biotechnology
About

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more

Proteomics International Laboratories Ltd (PIQ) - Net Assets

Latest net assets as of June 2025: AU$12.97 Million AUD

Based on the latest financial reports, Proteomics International Laboratories Ltd (PIQ) has net assets worth AU$12.97 Million AUD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$14.78 Million) and total liabilities (AU$1.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$12.97 Million
% of Total Assets 87.73%
Annual Growth Rate 9.17%
5-Year Change 70.41%
10-Year Change 1538.5%
Growth Volatility 82.21

Proteomics International Laboratories Ltd - Net Assets Trend (2014–2025)

This chart illustrates how Proteomics International Laboratories Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Proteomics International Laboratories Ltd (2014–2025)

The table below shows the annual net assets of Proteomics International Laboratories Ltd from 2014 to 2025.

Year Net Assets Change
2025-06-30 AU$12.97 Million +40.20%
2024-06-30 AU$9.25 Million +11.12%
2023-06-30 AU$8.32 Million +145.25%
2022-06-30 AU$3.39 Million -55.40%
2021-06-30 AU$7.61 Million +71.46%
2020-06-30 AU$4.44 Million +48.61%
2019-06-30 AU$2.99 Million -36.14%
2018-06-30 AU$4.68 Million +190.48%
2017-06-30 AU$1.61 Million +103.42%
2016-06-30 AU$791.42K -56.16%
2015-06-30 AU$1.81 Million -63.46%
2014-06-30 AU$4.94 Million --

Equity Component Analysis

This analysis shows how different components contribute to Proteomics International Laboratories Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 3634305300.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$47.64 Million 361.70%
Other Comprehensive Income AU$3.32 Million 25.20%
Total Equity AU$13.17 Million 100.00%

Proteomics International Laboratories Ltd Competitors by Market Cap

The table below lists competitors of Proteomics International Laboratories Ltd ranked by their market capitalization.

Company Market Cap
PLASTIQ.V.LOI.INH.EO -90
F:1R9
 		$24.70 Million
ALXPF
PINK:ALXPF
 		$24.72 Million
Aztek Teknoloji Urunleri Ticaret A.S.
IS:AZTEK
 		$24.72 Million
CCC
JSE:CCC
 		$24.72 Million
Wafangdian Bearing Co Ltd
SHE:200706
 		$24.70 Million
SRG Mining Inc
PINK:SRGMF
 		$24.69 Million
Sino Horizon Holdings Ltd
TW:2923
 		$24.68 Million
IDENIX PHARM
MU:NO9
 		$24.66 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Proteomics International Laboratories Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 9,412,518 to 13,170,446, a change of 3,757,928 (39.9%).
  • Net loss of 8,114,797 reduced equity.
  • Share repurchases of 11,203,130 reduced equity.
  • New share issuances of 11,203,125 increased equity.
  • Other comprehensive income increased equity by 1,045,347.
  • Other factors increased equity by 10,827,383.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-8.11 Million -61.61%
Share Repurchases AU$11.20 Million -85.06%
Share Issuances AU$11.20 Million +85.06%
Other Comprehensive Income AU$1.05 Million +7.94%
Other Changes AU$10.83 Million +82.21%
Total Change AU$- 39.92%

Book Value vs Market Value Analysis

This analysis compares Proteomics International Laboratories Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.63x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 1.17x to 3.63x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2014-06-30 AU$0.27 AU$0.32 x
2015-06-30 AU$0.07 AU$0.32 x
2016-06-30 AU$0.02 AU$0.32 x
2017-06-30 AU$0.03 AU$0.32 x
2018-06-30 AU$0.08 AU$0.32 x
2019-06-30 AU$0.04 AU$0.32 x
2020-06-30 AU$0.05 AU$0.32 x
2021-06-30 AU$0.07 AU$0.32 x
2022-06-30 AU$0.03 AU$0.32 x
2023-06-30 AU$0.07 AU$0.32 x
2024-06-30 AU$0.07 AU$0.32 x
2025-06-30 AU$0.09 AU$0.32 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Proteomics International Laboratories Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -61.61%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -844.95%
  • • Asset Turnover: 0.06x
  • • Equity Multiplier: 1.12x
  • Recent ROE (-61.61%) is above the historical average (-68.42%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 -4.99% -21.85% 0.22x 1.06x AU$-740.60K
2015 -63.66% -188.89% 0.24x 1.40x AU$-1.33 Million
2016 -167.86% -162.63% 0.50x 2.05x AU$-1.41 Million
2017 -56.93% -99.04% 0.32x 1.79x AU$-1.08 Million
2018 -30.80% -122.41% 0.21x 1.17x AU$-1.91 Million
2019 -69.66% -141.70% 0.41x 1.21x AU$-2.38 Million
2020 -39.29% -122.54% 0.26x 1.25x AU$-2.19 Million
2021 -37.58% -218.16% 0.15x 1.13x AU$-3.62 Million
2022 -146.53% -333.91% 0.28x 1.59x AU$-5.31 Million
2023 -74.39% -853.62% 0.07x 1.20x AU$-7.07 Million
2024 -67.74% -714.71% 0.08x 1.16x AU$-7.32 Million
2025 -61.61% -844.95% 0.06x 1.12x AU$-9.43 Million

Industry Comparison

This section compares Proteomics International Laboratories Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $31,815,679
  • Average return on equity (ROE) among peers: -60.84%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Proteomics International Laboratories Ltd (PIQ) AU$12.97 Million -4.99% 0.14x $24.70 Million
Adalta Ltd (1AD) $2.03 Million -265.03% 1.74x $171.91K
Algorae Pharmaceuticals Ltd (1AI) $2.88 Million -33.65% 0.18x $9.99 Million
ACRUX Ltd (ACR) $17.49 Million -17.99% 0.05x $2.16 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $11.42 Million
Arovella Therapeutics Ltd (ALA) $11.23 Million -77.89% 0.18x $39.76 Million
Anatara Lifesciences Ltd (ANR) $5.92 Million -48.49% 0.08x $718.75K
Bio-Gene Technology Ltd (BGT) $4.25 Million -56.43% 0.18x $2.33 Million
BTC Health Ltd (BTC) $11.34 Million -4.81% 0.03x $364.22
Cambium Bio Ltd (CMB) $8.27 Million -79.86% 0.16x $8.11 Million
Clinuvel Pharmaceuticals Ltd (CUV) $240.81 Million 15.02% 0.13x $251.65 Million